Pregnancy in Parkinson's disease: case report and discussion.

Department of Neurology, University of Maryland School of Medicine, 22 South Greene Street N4W46, Baltimore, MD 21201, USA.
Expert Review of Neurotherapeutics (Impact Factor: 2.83). 01/2009; 8(12):1799-805. DOI: 10.1586/14737175.8.12.1799
Source: PubMed

ABSTRACT Pregnancy in Parkinson's disease (PD) is an uncommon occurrence. Available reports suggest that there may be a worsening of PD symptom severity related to pregnancy. In this special report, medical literature on pregnancy in PD will be reviewed with regard to disease progression and the safety of antiparkinsonian medications. A case report of pregnancy in a woman with PD will be described. It is speculated that the symptoms of PD may be affected by changing hormone levels.

Download full-text


Available from: Roger J Mullins, Mar 09, 2015
1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The existence of a sex difference in Parkinson's disease (PD) is observed as related to several variables, including susceptibility of the disease, age at onset, and symptoms. These differences between men and women represent a significant characteristic of PD, which suggest that estrogens may exert beneficial effects against the development and the progression of the disease. This paper reviews the neuroprotective and neuromodulator effects of 17β-estradiol and progesterone as compared to androgens in the nigrostriatal dopaminergic (NSDA) system of both female and male rodents. The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mice model of PD and methamphetamine toxicity faithfully reproduce the sex differences of PD in that endogenous estrogen levels appear to influence the vulnerability to toxins targeting the NSDA system. Exogenous 17β-estradiol and/or progesterone treatments show neuroprotective properties against NSDA toxins while androgens fail to induce any beneficial effect. Sex steroid treatments show male and female differences in their neuroprotective action against methamphetamine toxicity. NSDA structure and function, as well as the distribution of estrogen receptors, show sex differences and may influence the susceptibility to the toxins and the response to sex steroids. Genomic and non-genomic actions of 17β-estradiol converge to promote survival factors and the presence of both estrogen receptors α and β are critical to 17β-estradiol neuroprotective action against MPTP toxicity.
    Frontiers in Endocrinology 09/2011; 2:35. DOI:10.3389/fendo.2011.00035
  • [Show abstract] [Hide abstract]
    ABSTRACT: A low-power Gbit/s operating bipolar standard cell LSI design methodology is described. It features a performance-driven layout, highly accurate static timing analysis, and CAD-based optimization for power dissipation. A 5.6-k-gate SDH signal-processing LSI operates at 1.6 Gbit/s with only 3.9 W power consumption
    Bipolar/BiCMOS Circuits and Technology Meeting, 1995., Proceedings of the 1995; 11/1995
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Pregnant patients are rarely encountered in the movement disorders clinic, but they present significant dilemmas regarding treatment and counseling for neurologists. While movement disorders in pregnancy once described those disorders arising de novo during pregnancy, such as chorea gravidarum or restless leg syndrome, advancing maternal age in Western countries will likely increase the number of women in whom pregnancy complicates a pre-existing movement disorder. Physicians treating these women must be aware of the impact of the movement disorder and its treatment on fertility, pregnancy, fetal development, lactation, and infant care. This review summarizes retrospective series and case reports to both guide clinicians and to stimulate and direct the design of prospective studies.
    Movement Disorders 04/2010; 25(6):665-71. DOI:10.1002/mds.23071 · 5.63 Impact Factor